News & Updates
Filter by Specialty:

How safe is sacubitril-valsartan plus spironolactone for ADHF?
Initiation of sacubitril-valsartan with spironolactone during hospitalization for acute decompensated heart failure (ADHF) does not result in more adverse drug reactions (ADRs), reports a study. However, patients on this regimen tend to develop hyperkalemia.
How safe is sacubitril-valsartan plus spironolactone for ADHF?
04 Jan 2025
Cuffless device may revolutionize hypertension management
A retrospective analysis shows that continual cuffless blood pressure (BP) monitoring may facilitate rapid and practical assessment of systolic BP (SBP) time-in-target range (TTR), an emerging metric of hypertension control.
Cuffless device may revolutionize hypertension management
02 Jan 2025
NT-proBNP predicts cardiorenal complications in Chinese patients with T2D
Elevated N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels independently predict cardiorenal complications in Chinese patients with type 2 diabetes (T2D) and can be utilized as a clinical prognostic biomarker for risk stratification to enable more intensive organ-protective treatment in those at risk, a study involving 1,993 patients enrolled in the Hong Kong Diabetes Biobank has shown.
NT-proBNP predicts cardiorenal complications in Chinese patients with T2D
30 Dec 2024
Left heart geometry changes predict NOAF hypertensive patients
The changes seen in left heart geometry may be used as a marker to predict the development of new-onset atrial fibrillation (NOAF) in patients with hypertension, suggests a study.
Left heart geometry changes predict NOAF hypertensive patients
28 Dec 2024
Volatile organic compounds up hypertension risk
A recent study has found epidemiological evidence pointing to an association between environmental pollutants and hypertension. This finding calls attention to the contribution of nonoccupational volatile organic compounds (VOCs) to the risk of hypertension in the general population.